Citigroup’s Rapport Therapeutics RAPP Stock Holding History

Citigroup’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$611K	Sell	18,190 -6,183	-25%	-$267K	﹤0.01%	3638
2026 Q2	$1.02M	Sell	24,373 -54,426	-69%	-$2M	﹤0.01%	3434
2026 Q1	$2.47M	Buy	78,799 +22,315	+40%	+$628K	﹤0.01%	2531
2025 Q4	$1.71M	Buy	56,484 +54,714	+3,091%	+$1.51M	﹤0.01%	2763
2025 Q3	$52.6K	Sell	1,770 -5,283	-75%	-$94.2K	﹤0.01%	4478
2025 Q2	$80.2K	Sell	7,053 -8,032	-53%	-$85.2K	﹤0.01%	4523
2025 Q1	$151K	Buy	15,085 +5,508	+58%	+$71.5K	﹤0.01%	4351
2024 Q4	$170K	Sell	9,577 -3,197	-25%	-$70.8K	﹤0.01%	4510
2024 Q3	$262K	Buy	+12,774	New	+$274K	﹤0.01%	4158

Other funds holding RAPP

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return

Citigroup's RAPP Position: Q3 2026 in Review

Citigroup reduced its Rapport Therapeutics (RAPP) stake by 25% in Q3 2026, selling an estimated $267K and leaving 18,190 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #3638.

Citigroup first reported a position in RAPP in Q3 2024 and has held it in 9 quarters since. The position peaked at $2.47M in Q1 2026. 41 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

Citigroup held 18,190 shares of Rapport Therapeutics worth $611K as of Q3 2026.
Citigroup sold 6,183 Rapport Therapeutics shares in Q3 2026, an estimated $267K.
Rapport Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3638 holding.
Citigroup first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 9 quarters since.
Citigroup's Rapport Therapeutics position peaked at $2.47M in Q1 2026.
41 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.